US005591736A

United States Patent [19]

Walser

[11] **Patent Number: 5,591,736**

[45] **Date of Patent: Jan. 7, 1997**

[54] **METHOD OF RETARDING THE PROGRESSION OF CHRONIC RENAL FAILURE**

[75] Inventor: **Mackenzie Walser**, Ruxton, Md.

[73] Assignee: **The Johns Hopkins University**, Baltimore, Md.

[21] Appl. No.: **497,958**

[22] Filed: **Jul. 3, 1995**

[51] **Int. Cl.**[6] **A61K 31/56**

[52] **U.S. Cl.** **514/178**

[58] **Field of Search** 514/178

[56] **References Cited**

U.S. PATENT DOCUMENTS

4,100,160	7/1978	Walser	424/274
4,228,099	10/1980	Walser	260/501.11
4,352,814	10/1982	Walser	424/273 R
4,496,556	1/1985	Orentreich	514/178
4,542,129	9/1985	Orentreich	514/178
4,752,619	6/1988	Walser et al.	514/564
5,175,144	12/1992	Walser	514/2

OTHER PUBLICATIONS

Abstract (Accession Number QD586–0004) of Araneo et al., "Dehydropepiandrosterone Functions as More than an Anti-glucocorticoid in Preserving Immunocompetence after Thermal Injury" *Endocrinology* 136(2): 393–401 (Feb. 1995).

Kalimi et al., "Anti–Glucocorticoid Effects of Dehydroepiandrosterone (DHEA)", *Mol. Cell. Biochem.* 131:99–104 (1994).

Lucas et al., "Prevention of Autoantibody Formation and Prolonged Survival in New Zealand Black/New Zealand White F_1 Mice Fed Dehydroisoandrosterone", *J. Clin. Invest.* 75:2091–2093 (1995).

McIntosh et al., "Strain Differences in the Dose–Response Curves of Adrenalectomized, Starved–Refed Rats to Dehydroepiandrosterone (DHEA) (42657)", *Proc. Soc. Exp. Biol. Med.* 187:216–222 (1988).

Meikle et al., "The Presence of a Dehydroepiandrosterone–Specific Receptor Binding Complex in Murine T Cells", *J. Steroid Biochem. Molec. Biol.* 42(3/4):293–304 (1992).

Meikle et al., "Adrenal Androgen Secretion and Biologic Effects", *Endrocinol. Metab. Clinics N. Amer.* 20(2):381–400 (1991).

Pashko et al., "Inhibition of Proteinuria Development in Aging Sprague–Dawley Rats and C57BL/6 Mice by Long–Term Treatment with Dehydroepiandrosterone", *J. Gerontol.* 41(4):433–438 (1986).

Suzuki et al., "Dehydroepiandrosterone Enhances IL2 Production and Cytotoxic Effector Function of Human T Cells", *Clin. Immunol. Immunopath.* 61:202–211 (1991).

Svec et al., "The Effect of DHEA Given Chronically to Zucker Rats (43883)", *Proc. Soc. Exp. Biol. Med.* 209:92–97 (1995).

van Vollenhoven et al., "An Open Study of Dehydroepiandrosterone in Systemic Lupus Erythematosus", *Arthritis Rheum.* 37(9): 1305–1310 (1994).

Walser et al., "Progression of Chronic Renal Failure is Related to Glucocorticoid Production", *Kidney Int.* 34:859–866 (1988).

Walser et al., "Progression of Chronic Renal Failure in Patients Given Ketoacids Following Amino Acids", *Kidney Int.* 32:123–128 (1987).

Winer et al., "Preservation of Normal Adrenal Androgen Secretion in End Stage Renal Disease", *Metabolism* 31(3):269–273 (1982).

Zumoff et al., "Subnormal Plasma Adrenal Androgen Levels in Men with Uremia", *J. Clin. Endocrin. Metab.* 51(4):801–805 (1980).

Primary Examiner—Raymond Henley, III

Attorney, Agent, or Firm—Panitch, Schwarze, Jacobs & Nadel, P.C.

[57] **ABSTRACT**

The progression of chronic renal failure in humans may be retarded by administration of dehydroepiandrosterone (DHEA) in effective amounts. The administration of DHEA is preferably oral at a dose of about 400 to 1600 mg/day. Patients suffering from severe chronic renal failure are also preferably maintained on a protein-restricted diet during DHEA administration.

12 Claims, No Drawings